Introduction
============

Demonstration of airflow obstruction is an essential requirement in the diagnosis of chronic obstructive pulmonary disease (COPD). The forced expiratory volume in one second (FEV~1~) is the spirometric index most commonly used to detect the presence of COPD, to characterize its severity and to determine bronchodilator response ([@b2-copd-2-651]). Although FEV~1~ is a strong prognostic indicator in COPD, it correlates poorly with both dyspnea level and limitation to exercise performance ([@b14-copd-2-651]), arguably the symptoms which are of most relevance to patients.

As well as being defined by the presence of airflow obstruction, COPD is characterized by dynamic hyperinflation of the lungs. Recent studies suggest that improvements in spirometric indices of hyperinflation in COPD are more closely related to dyspnea relief than are other more commonly-used measurements of airway caliber such as the FEV~1~ ([@b13-copd-2-651]; [@b14-copd-2-651]; [@b22-copd-2-651]; [@b4-copd-2-651]). Traditionally, the more complex measurements of total lung capacity (TLC) and functional residual capacity (FRC) have been used to detect and quantify hyperinflation. However, the inspiratory capacity (IC) provides an indirect measurement of end expiratory lung volume and is a technically simpler test.

Inspiratory capacity has been shown to increase significantly in 'irreversible' COPD ([@b17-copd-2-651]; [@b20-copd-2-651]; [@b12-copd-2-651]), even in the absence of improvement in FEV~1~ ([@b20-copd-2-651]; [@b12-copd-2-651]) indicating that functional improvement is possible, independent of changes in maximal flow. Furthermore, increases in IC following bronchodilator are significantly correlated with improvements in dyspnea at rest ([@b14-copd-2-651]; [@b22-copd-2-651]; [@b7-copd-2-651]), with dyspnea during exercise ([@b13-copd-2-651]; [@b14-copd-2-651]), and with exercise performance ([@b14-copd-2-651]; [@b8-copd-2-651]). Monitoring IC has also been useful in describing changes in dynamic hyperinflation in response to oxygen therapy in COPD ([@b1-copd-2-651]), and in response to induced bronchoconstriction in asthma ([@b11-copd-2-651]; [@b21-copd-2-651]).

These studies suggest that the measurement of IC could potentially be incorporated into the assessment and management of COPD as a simple, objective and clinically relevant measurement of disease status. The majority of previous studies investigating the utility of IC measurements in COPD have been performed in stable disease. The question of the applicability and usefulness of IC measurements during acute exacerbations of COPD has received little attention. We wished to determine if there is a role for IC measurement in the clinical management of acute exacerbations of COPD. In addition, given the relationship between IC and dyspnea observed in induced bronchoconstriction in asthma ([@b11-copd-2-651]; [@b21-copd-2-651]), IC measurement may also have a role in the management of asthma exacerbations.

The aims of the present study were (1) to investigate the relationships between dyspnea and IC during acute exacerbations of COPD and asthma, and (2) to assess the relationship between changes in IC and in dyspnea over the course of a hospital admission for an exacerbation of COPD or asthma.

Methods
=======

Subjects
--------

Adults requiring hospital admission for management of acute exacerbations of either asthma or COPD were prospectively recruited within 24 hours of admission. All subjects had received standard bronchodilator and corticosteroid therapy in the Accident and Emergency Department. Exclusion criteria were inability to reliably perform spirometry or to comprehend the use of the Borg dyspnea scale. The study protocol was approved by our institution's medical research ethics committee and all subjects gave written informed consent.

Respiratory function tests
--------------------------

Respiratory function tests were performed using a computerized spirometry system (Sensormedics Vmax, Yorba Linda, USA) on two separate occasions: (1) within 24 hours of admission and (2) immediately prior to discharge from hospital. At least 4 hours abstinence from short-acting beta-2 agonists and anticholinergic therapy was required prior to each set of tests. A minimum of one minute of quiet tidal breathing was allowed on the mouthpiece-flowmeter assembly prior to each of at least three measurements of inspiratory capacity (IC) and slow vital capacity (VC). Best VC and average of three IC measurements matching to within 10% were used for analysis. Following these measurements, maximal flow volume curves were performed in accordance with ATS recommendations ([@b3-copd-2-651]). All spirometric testing was repeated 10 minutes after supervised administration of 200 μg of salbutamol delivered by metered dose inhaler via spacer. Resting dyspnea scores using the modified Borg scale ([@b5-copd-2-651]) were obtained immediately prior to baseline and again immediately prior to post bronchodilator respiratory function testing. All baseline testing was performed within 24 hours of admission, and all tests were repeated in an identical fashion at the time of hospital discharge.

Statistical analyses
--------------------

Student's t-test was used for statistical analysis of paired comparisons and linear correlation used to detect relationships between variables. A p value of \<0.05 was considered statistically significant.

Results
=======

Twelve subjects with asthma and nine with COPD were recruited for the study and performed baseline measurements, however complete data was obtained in ten subjects with asthma and in eight with COPD. Reasons for non-completion were, in all cases, unwillingness to repeat spirometric measurements at the time of discharge. Only results from those subjects who completed the study are included in this report.

Subject characteristics are shown in [Table 1](#t1-copd-2-651){ref-type="table"}. Subjects in the asthma group were younger and predominantly female. The COPD group was predominantly male and had a higher pack year history of cigarette smoking.

Acute changes after bronchodilator
----------------------------------

[Tables 2a](#t2a-copd-2-651){ref-type="table"} and [2b](#t2b-copd-2-651){ref-type="table"} show the respiratory function data at both visits to the laboratory (within 24 hours of admission and at the time of discharge) for the asthma and COPD groups respectively. There were statistically significant acute improvements in dyspnea following bronchodilator for both patient groups on both visits. In addition, there were small acute bronchodilator improvements in VC at admission and in IC at discharge in the asthmatic group. No other parameter achieved statistically significant change following bronchodilator. [Figure 1](#f1-copd-2-651){ref-type="fig"} shows spirometric and dyspnea values for individual patients.

Changes over the admission
--------------------------

Respiratory function data for both groups at discharge are shown in [Tables 2a](#t2a-copd-2-651){ref-type="table"} and [2b](#t2b-copd-2-651){ref-type="table"}. Post-bronchodilator values were considered to provide more appropriate data for comparison over the course of the admission. The asthma group showed significant improvements in all measures of respiratory function (p = 0.05 for FEV~1~, p = 0.05 for VC, p = 0.04 for FEV~1~/VC and p = 0.006 for IC), whereas the COPD group showed no statistically significant changes. In contrast, resting dyspnea scores did not alter over the course of the admission in the asthma group, however there was a small improvement in resting dyspnea in the COPD group (p = 0.04).

Comparisons between asthma and COPD
-----------------------------------

Degree of airflow obstruction as measured by the FEV~1~/VC ratio was more severe in the COPD group compared with the asthma group: 42% versus 63% at admission, 42% versus 70% at discharge (p \< 0.0001 for both). Although there was no statistical difference between the admission FEV~1~ for the asthma and COPD groups, at discharge the FEV~1~ was significantly higher in the asthma group (p = 0.016). Thus, notable differences were observed between the two patient groups in the changes in measured indices over the course of the admission. Spirometric indices improved in the asthma group, and dyspnea scores improved in the COPD group.

Correlations between parameters
-------------------------------

Acute changes in lung function parameters and in dyspnea scores following inhaled bronchodilator are shown in [Figure 2](#f2-copd-2-651){ref-type="fig"} and reveal no significant relationships in either patient group. Data obtained at time of discharge similarly showed no significant correlation between these measurements. There was also no significant correlation between changes in these measures over the course of the admission ([Figure 3](#f3-copd-2-651){ref-type="fig"}).

Discussion
==========

We report an absence of correlation observed between change in dyspnea score and change in IC over the course of a hospital admission for treatment of exacerbations of asthma or COPD.

The theoretical reasoning that reductions in end expiratory lung volume should lead to improved lung mechanics and decreased work of breathing in COPD has been supported by a number of clinical studies over the past decade ([@b13-copd-2-651], [@b14-copd-2-651]; [@b22-copd-2-651]; [@b4-copd-2-651]). These studies have demonstrated that measures of lung hyperinflation correlate more strongly with dyspnea at rest and during exercise and with exercise performance than does FEV~1~. This work suggests that the emphasis in monitoring disease status in COPD should be shifted away from measures of airway caliber and function to measures of the degree of lung hyperinflation. Whilst functional residual capacity (FRC) and other lung volumes (such as residual volume and total lung capacity) have traditionally been used to describe lung hyperinflation, their measurement requires sophisticated, expensive instrumentation which is not always readily accessible. Relying on the assumption that total lung capacity does not change, IC can be used to provide a surrogate estimate of lung hyperinflation and requires no more than a simple spirometer for its measurement. Assessing changes in IC has been proposed as an important predictor of therapeutic response to bronchodilator therapy in COPD ([@b20-copd-2-651]; [@b14-copd-2-651], [@b12-copd-2-651]; [@b9-copd-2-651]).

For the COPD group, there was no change in the mean IC over the admission and no correlation between change in IC and change in dyspnea. However it was noted that the COPD patients who showed the largest improvement in IC over the admission (410 ml increase) also showed the largest improvement in resting dyspnea (−2 in Borg score). It has been suggested that an improvement in IC of equal to or greater than 10% of the predicted value corresponds with a real improvement in exercise performance ([@b14-copd-2-651]). Four of the ten patients in the asthma group and two of eight COPD patients exhibited such a change in IC over the course of the admission. However there were no significant differences in the changes in dyspnea scores between these 'responders' and the rest of the groups. This also applies to those who had at least a 10% of predicted acute improvement in IC in response to bronchodilator (two of ten and two of eight at admission, and two of ten and one of eight at discharge for asthma and COPD respectively).

Given that IC has been shown to provide a simple measure of hyperinflation which correlates with symptoms of dyspnea and exercise intolerance, it is not unreasonable to expect that IC should provide a useful index to monitor disease state during acute exacerbations of COPD. Our data show that over the course of an admission for treatment of disease exacerbations there was a measurable improvement in all spirometric indices in the asthma group, but in none for the COPD group. This is a not unexpected result for a measure of ventilatory function, given the nature of the two diseases -- at least partly reversible obstruction for asthma, but essentially fixed airways disease for COPD.

Our data show that IC did not change significantly over an average 3 day hospital admission for COPD exacerbation. This is a similar finding to that of [@b16-copd-2-651] who did not find any significant change over 7 days of recovery in a group of 20 COPD patients with less severe exacerbations, most of which did not require hospitalization. They did however find significant improvements in IC at 14 days which coincided with dyspnea improvements.

The observed improvement in resting dyspnea in the COPD group despite the lack of measurable physiological change may relate to the known euphoriant effect of corticosteroids in this patient group. There may also have also been a potential 'I am being discharged therefore I must be feeling better' phenomenon, however an improvement in dyspnea was not observed in the asthmatic group where a similar effect could be expected. Dyspnea in COPD is likely multifactorial in origin, with hyperinflation being only one of several mechanisms which may induce this symptom. Other factors which may impact on the cognitive sensation of dyspnea include the mechanical status of the chest (including degree of airflow obstruction) and the degrees of integration of respiratory afferent activity, respiratory motor drive, affective state, attention, experience and learning which exist in the individual patient ([@b15-copd-2-651]).

In our asthma group, self-perceived dyspnea on discharge from hospital did not improve despite the improvement in ventilatory function. In asthma, the perception of dyspnea during induced bronchoconstriction is known to be diminished in the presence of baseline airflow obstruction ([@b6-copd-2-651]). This is possibly due to a developing adaptation to poor lung function during periods of worsening asthma ([@b19-copd-2-651]). At the time of admission when our subjects with asthma are clearly in a state of suboptimal asthma control, it is not unreasonable to expect poor perception of dyspnea and therefore dyspnea ratings somewhat unrelated to airway caliber. There is also evidence that perception of dyspnea improves with steroid therapy ([@b19-copd-2-651]) and given that systemic corticosteroid therapy provides the mainstay of inpatient asthma management, our asthma patients are probably better perceivers of bronchial status at discharge compared with at admission. It is therefore not surprising that dyspnea on discharge from hospital did not improve despite improvement in ventilatory function.

The utility of IC as a measure of lung hyperinflation has been shown to be closely related to dyspnea during methacholine-induced bronchoconstriction in asthma ([@b11-copd-2-651]; [@b21-copd-2-651]). Its use in assessing bronchodilator response has received less interest in asthma than in COPD, presumably because of the utility of monitoring FEV~1~ in this disease. In one study in stable, mild asthma there was no correlation between change in dyspnea with change in FRC following bronchodilator ([@b10-copd-2-651]), and a similar finding in another study during acute exacerbations of asthma ([@b18-copd-2-651]). Our data support these findings and differ from those assessing relationships between dyspnea and IC during induced bronchoconstriction ([@b11-copd-2-651]; [@b21-copd-2-651]). The differences in nature of onset of bronchoconstriction could explain these contrasting findings -- acute bronchoconstriction from a relatively well preserved baseline is quite different from the slowly progressing deterioration that often precedes an exacerbation. Symptom perception is likely to be heightened in the former case whereas an adaptation or tolerance to impaired function may develop in the latter.

The lack of association between a change in IC and a change in dyspnea was not simply due to a lack of statistical power. Based on the data in the current study and assuming an α (significance) of 0.05 and a β (power) of 0.8, 78 subjects with asthma and 51 with COPD would have had to be tested to find a statistically significant association. These large numbers suggest the test has little clinical utility during exacerbations of COPD or asthma.

In summary, we have not been able to demonstrate any relationship between patient-perceived dyspnea and spirometric measurements of ventilatory function during acute exacerbations of asthma or COPD. In particular, changes in inspiratory capacity in these two disease states were not found to correlate with changes in dyspnea either as an acute response to bronchodilator, or in response to changes elicited during a hospital admission. A role for IC monitoring in the management of acute exacerbations of COPD and asthma has not been identified.

![Respiratory function and dyspnea scores at admission and at discharge for the asthma group (•) and for the COPD group (○). Each data pair represents the pre and post bronchodilator value obtained for each individual patient.](copd-2-651f1){#f1-copd-2-651}

![Acute changes in FEV~1~ and IC plotted against changes in dyspnea scores in response to inhaled bronchodilator at time of admission for both the asthma group (•) and for the COPD group (○). Correlation coefficients are not significant for all groups.](copd-2-651f2){#f2-copd-2-651}

![Changes in FEV~1~ and IC plotted against changes in dyspnea scores over the course of the admission for both the asthma group (•) and for the COPD group (○). Correlation coefficients are not significant for all groups.](copd-2-651f3){#f3-copd-2-651}

###### 

Admission characteristics for all subjects completing the study. Values quoted are means (range). Statistical difference between groups indicated by \* (p ≤ 0.001) or \# (p \< 0.0001)

                              **Asthma**                 **COPD**
  --------------------------- -------------------------- -----------------
  Number of subjects          10                         8
  Male/Female                 1/9                        7/1
  Age (years)\*               43 (19--71)                71 (66--73)
  BMI (kg/m^2^)               30 (20--39)                26 (21--33)
  Smoking history             2 current, 3 ex, 5 never   3 current, 5 ex
  Pack years \#               3 (0--22)                  64 (25--116)
  Hospital admission (days)   3.3                        3.4
  FEV~1~ (% pred.)            54 (37--89)                42 (23--60)
  VC (% pred.)                74 (56--112)               79 (59--95)
  FEV~1~/VC (%)\*             61 (44--79)                40 (30--49)
  IC (% pred.)                94 (73--124)               91 (55--117)
  Dyspnea (Borg)              3.9 (0.5--7.0)             3.5 (1.0--5.0)

###### 

Mean (SEM) respiratory function and dyspnea data for patients with asthma. Baseline to post bronchodilator (Post BD) t-test comparisons are indicated by the p-value in the table

                   **Admission**   **Discharge**                                          
  ---------------- --------------- --------------- ---------- ------------- ------------- -----------
  FEV~1~ (L)       1.46 (0.21)     1.60 (0.22)     0.10       1.95 (0.27)   2.01 (0.28)   0.19
  VC (L)           2.37 (0.26)     2.52 (0.28)     **0.04**   2.74 (0.31)   2.79 (0.30)   0.14
  FEV~1~/VC (%)    61 (3.8)        63 (2.8)        0.51       70 (3.2)      70 (2.8)      0.67
  IC (L)           2.03 (0.18)     2.15 (0.19)     0.08       2.26 (0.18)   2.36 (0.17)   **0.02**
  Dyspnea (Borg)   3.9 (0.6)       2.6 (0.3)       **0.02**   2.6 (0.4)     2.0 (0.3)     **0.005**

###### 

Mean (SEM) respiratory function and dyspnea data for patients with COPD. Baseline to post bronchodilator (BD) t-test comparisons are indicated by the p-value in the table

                   **Admission**   **Discharge**                                          
  ---------------- --------------- --------------- ---------- ------------- ------------- ----------
  FEV~1~ (L)       1.05 (0.13)     1.16 (0.14)     0.12       1.08 (0.11)   1.13 (0.11)   0.22
  VC (L)           2.58 (0.23)     2.77 (0.27)     0.06       2.63 (0.24)   2.70 (0.27)   0.49
  FEV~1~/VC (%)    40 (2.5)        42 (2.8)        0.55       41 (2.1)      42 (2.1)      0.11
  IC (L)           1.93 (0.19)     2.05 (0.24)     0.09       1.94 (0.15)   2.03 (0.17)   0.27
  Dyspnea (Borg)   3.5 (0.5)       2.7 (0.4)       **0.04**   2.6 (0.4)     2.1 (0.3)     **0.02**
